Loading chart data...
Danaher Corporation is trading lower today, moving in line with a broader trend of weakness among its peers in the medical diagnostics and research industry, such as Crane Company and Mettler-Toledo International, which also saw declines. While there was no specific company news released over the last 48 hours to drive the price action, recent regulatory filings confirm that major institutional investors, including BlackRock, have established new positions in the company during the second quarter. The stock continues to hold a position above its 50-day moving average as investors digest recent leadership changes, including the appointment of Julie Sawyer Montgomery as the new President and CEO announced earlier this month.
That explains the day. Whether DHR is a business worth owning is a longer question. Koyfin has the ten-year financials, margin history and valuation to answer it — 20% off for WhyTheMove readers.
No significant catalyst events detected.
DHR moved for a reason you can read above. What the company earns, owns and guides to is a separate record. Koyfin is where the question moves from today's move to the business behind it — analyst estimates, filings and earnings transcripts.
Research DHR in Koyfin →7-day full-access trial · 20% off paid plans